Advertisement
INO vs PCSA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INO is a Hold and PCSA is a Hold.
INO in downward trend: price expected to drop as it breaks its higher Bollinger Band on November 02, 2026
INO broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 33 similar instances where the stock broke above the upper band. In 29 of the 33 cases the stock fell afterwards. This puts the odds of success at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for INO moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 17 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 47 cases where INO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for INO entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on INO as a result. In 56 of 71 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for INO just turned positive on November 02, 2026. Looking at past instances where INO's MACD turned positive, the stock continued to rise in 30 of 40 cases over the following month. The odds of a continued upward trend are 75%.
INO moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for INO crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where INO advanced for three days, in 185 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. INO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (28.741) is normal, around the industry mean (3.498). P/E Ratio (-1.180) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
PCSA's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for PCSA turned positive on October 12, 2026. Looking at past instances where PCSA's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PCSA's RSI Oscillator exited the oversold zone, 40 of 47 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on PCSA as a result. In 66 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
PCSA moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PCSA crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +6.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where PCSA advanced for three days, in 183 of 219 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 49 of 57 cases where PCSA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 33 cases where PCSA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-16.725) is normal, around the industry mean (3.498). P/E Ratio (2.923) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. PCSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCSA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
INO | PCSA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 92 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 36 | 63 | |
P/E GROWTH RATING 1..100 | 60 | 63 | |
SEASONALITY SCORE 1..100 | n/a | 1 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PCSA's Valuation (10) in the null industry is significantly better than the same rating for INO (90) in the Medical Specialties industry. This means that PCSA’s stock grew significantly faster than INO’s over the last 12 months.
PCSA's Profit vs Risk Rating (100) in the null industry is in the same range as INO (100) in the Medical Specialties industry. This means that PCSA’s stock grew similarly to INO’s over the last 12 months.
PCSA's SMR Rating (100) in the null industry is in the same range as INO (100) in the Medical Specialties industry. This means that PCSA’s stock grew similarly to INO’s over the last 12 months.
INO's Price Growth Rating (36) in the Medical Specialties industry is in the same range as PCSA (63) in the null industry. This means that INO’s stock grew similarly to PCSA’s over the last 12 months.
INO's P/E Growth Rating (60) in the Medical Specialties industry is in the same range as PCSA (63) in the null industry. This means that INO’s stock grew similarly to PCSA’s over the last 12 months.
| INO | PCSA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 85% | 2 days ago 85% |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 79% | 1 day ago 81% |
| MACD ODDS (%) | 1 day ago 75% | 1 day ago 87% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 76% | 1 day ago 90% |
| Advances ODDS (%) | 15 days ago 79% | 3 days ago 84% |
| Declines ODDS (%) | 6 days ago 88% | 10 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 88% | N/A |
| Aroon ODDS (%) | 1 day ago 82% | 1 day ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INO’s FA Score shows that 0 FA rating(s) are green while PCSA’s FA Score has 1 green FA rating(s).
- INO’s FA Score: 0 green, 5 red.
- PCSA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INO’s TA Score shows that 5 TA indicator(s) are bullish while PCSA’s TA Score has 7 bullish TA indicator(s).
- INO’s TA Score: 5 bullish, 5 bearish.
- PCSA’s TA Score: 7 bullish, 2 bearish.
Price Growth
INO (@Biotechnology) experienced а -12.65% price change this week, while PCSA (@Biotechnology) price change was -3.61% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
INO is expected to report earnings on Mar 02, 2027.
PCSA is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
INO and
Correlation & Price change
A.I.dvisor indicates that over the last year, INO has been loosely correlated with AXON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To INO | 1D Price Change % | ||
|---|---|---|---|---|
| INO | 100% | +1.72% | ||
| AXON - INO | 53% Loosely correlated | +4.26% | ||
| ARRY - INO | 52% Loosely correlated | +9.94% | ||
| LPCN - INO | 41% Loosely correlated | N/A | ||
| AMRN - INO | 39% Loosely correlated | -0.34% | ||
| PCSA - INO | 38% Loosely correlated | N/A | ||
More | ||||
PCSA and
Correlation & Price change
A.I.dvisor indicates that over the last year, PCSA has been loosely correlated with RADX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if PCSA jumps, then RADX could also see price increases.
| Ticker / NAME | Correlation To PCSA | 1D Price Change % | ||
|---|---|---|---|---|
| PCSA | 100% | N/A | ||
| RADX - PCSA | 48% Loosely correlated | -2.35% | ||
| INO - PCSA | 38% Loosely correlated | +1.72% | ||
| ONCO - PCSA | 35% Loosely correlated | +8.36% | ||
| IBO - PCSA | 32% Poorly correlated | -6.93% | ||
| EDIT - PCSA | 28% Poorly correlated | -4.99% | ||
More | ||||